A carregar...

Adaptive resistance to RAF inhibitors in melanoma

The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the door to new treatment options, which have resulted in significantly better patient outcomes. Treatments such as the FDA-approved RAF inhibitor vemurafenib, and the more recently approved dabrafenib and t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kugel, Curtis H., Aplin, Andrew E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4212018/
https://ncbi.nlm.nih.gov/pubmed/24828387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!